Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin plus G-CSF in cancer patients

被引:7
|
作者
Joshi, SS
Miller, K
Jackson, JD
Warkentin, P
Kessinger, A
机构
[1] Univ Nebraska, Med Ctr 986395, Dept Cell Biol & Anat, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA
[3] Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
关键词
erythropoietin; G-CSF blood stem cells; mobilization; cytotoxic effector cell; functions; phenotypes;
D O I
10.1080/146532400539017
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background Although the recombinant granulocyte colony-stimulating factor (G-CSF) is a good CD34 cell mobilizer; the effects of G-CSF mobilization on the immune effector function of the individual is not always optimal. We studied the functional and phenotypic properties of peripheral blood stem cells (PBSC) collected from 15 cancer patients mobilized with G-CSF plus recombinant erythropoietin (EPO). Methods The patients received EPO (300 U/kg) and (G-CSF 10 mu g/kg) per day as mobilizing cytokines and an autologous graft product was collected with at least daily apheresis procedures until a target number of CD34 cells and mononuclear cells were obtained Mononuclear cells from the first four PBSC collections were tested for their natural killer (NK), activated NK and lymphokine activated killer (LAK) cytotoxicity in vitro against K562 and Raji tumor target cells. Results There was a significant increase in NK, activated NK and LAK cytotoxicity in EPO + G-CSF mobilized cells when compared to mononuclear cells from premobilization blood baseline values Although there was no increase in CD3(+) T cells there was a significant increase in myeloid cells (CD14(+)), B-cells (CD20(+)) and NK cells (CD56(+)) following mobilization. There was no difference in T cell response to the mitogens PHA and Con-A, but there was an increase in B-cell response to PWM following mobilization. Thus, the combination of EPO + G-CSF not only mobilized hematopoietic precursor cells but also increased the number of immune effector cells in the PBSC collections.
引用
收藏
页码:15 / 24
页数:10
相关论文
共 50 条
  • [21] Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma
    Nazha, Aziz
    Cook, Rachel
    Vogl, Dan T.
    Mangan, Patricia A.
    Hummel, Kimberly
    Cunningham, Kathleen
    Luger, Selina
    Porter, David
    Schuster, Stephen J.
    O'Doherty, Una
    Sell, Mary
    Siegel, Don L.
    Stadtmauer, Edward A.
    BLOOD, 2009, 114 (22) : 844 - 844
  • [22] Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma
    Jelinek, Tomas
    Adamusova, Lucie
    Popkova, Tereza
    Tvrda, Ivana
    Smejkalova, Jana
    Simicek, Michal
    Salounova, Dana
    Kascak, Michal
    Mihalyova, Jana
    Plonkova, Hana
    Duras, Juraj
    Navratil, Milan
    Hajek, Roman
    Koristek, Zdenek
    BONE MARROW TRANSPLANTATION, 2019, 54 (07) : 1107 - 1114
  • [23] Use of concurrent G-CSF plus GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells in children with malignant disease
    Madero, L
    González-Vicent, M
    Molina, J
    Madero, R
    Quintero, V
    Díaz, MA
    BONE MARROW TRANSPLANTATION, 2000, 26 (04) : 365 - 369
  • [24] Higher efficacy of intermediate dose cytarabine plus G-CSF compared to cyclophosphamide plus G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma
    Bogucka-Fedorczuk, Aleksandra
    Czyz, Anna
    Kalicinska, Elzbieta
    Sawicki, Mateusz
    Laszkowska-Lewko, Magdalena
    Wicherska-Pawlowska, Katarzyna
    Rybka, Justyna
    Szeremet, Agnieszka
    Prajs, Iwona
    Szymczak, Donata
    Wrobel, Tomasz
    JOURNAL OF CLINICAL APHERESIS, 2020, 35 (04) : 246 - 254
  • [25] High Efficacy of Stem Cell Mobilization With Etoposide plus Cytarabine Plus G-CSF in Patients With Multiple Myeloma
    Zhu, Zhijuan
    Li, Xiaofan
    Liu, Yiping
    Chen, Ping
    Chen, Xianling
    Li, Hua
    Huang, Jiafu
    Chen, Yuanzhong
    Li, Nainong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] A Comparison of Chemotherapy plus G-CSF Versus Plerixafor (Mazobil®) plus G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide.
    Mark, Tomer M.
    Rossi, Adriana C.
    Pearse, Roger N.
    Coleman, Morton
    Bernstein, David
    Zafar, Faiza
    Dergis, Usama
    Shore, Tsiporah B.
    Niesvizky, Ruben
    BLOOD, 2010, 116 (21) : 928 - 929
  • [27] Biosimilar G-CSF Versus Originator G-CSF for Autologous Peripheral Blood Stem Cell Mobilization: A Comparative Analysis of Mobilization and Engraftment
    Stakiw, Julie
    Sabry, Waleed
    Elemary, Mohamed
    Bosch, Mark J.
    Danyluk, Pat
    Aggarwal, Vibhuti
    Mondal, Prosanta
    BLOOD, 2018, 132
  • [28] Immunophenotyping of peripheral blood mononuclear cells collected by cytotoxic and cytotoxic/G-CSF mobilization
    Kubota, A
    Nagafuji, K
    Harada, M
    Otsuka, T
    Harada, N
    Eto, T
    Takamatsu, Y
    Fukuda, T
    Shimoda, K
    Inaba, S
    Okamura, S
    Niho, Y
    CLINICAL AND LABORATORY HAEMATOLOGY, 1996, 18 (03): : 181 - 185
  • [29] Stem cell mobilization with G-CSF following standard ESHAP chemotherapy in patients with lymphoma.
    Berdeja, JG
    Ambinder, RF
    Jones, RJ
    Diehl, LF
    Noga, SS
    Sickler, J
    Carter-Brookins, D
    Piantadosi, S
    Flinn, IW
    BLOOD, 2001, 98 (11) : 179A - 180A
  • [30] Decreased immune effector cells in G-CSF mobilized normal donor blood stem cell harvests.
    Joshi, SS
    Desler, MM
    Pavletic, ZS
    Tarantolo, SR
    Kessinger, A
    Bishop, MR
    FASEB JOURNAL, 1999, 13 (04): : A322 - A322